Diabetic Retinopathy: Stages & Screening Guidelines

Why Diabetic Retinopathy Matters

Diabetic retinopathy (DR) is damage to the blood vessels of the retina caused by diabetes. It is one of the leading causes of preventable blindness in working-age adults worldwide. The word “preventable” carries the whole message of this guide: with timely screening and treatment, most vision loss from diabetic retinopathy can be avoided.

A defining challenge of the disease is that early stages cause no symptoms. A patient with developing retinopathy typically sees perfectly well — until the disease reaches an advanced stage, at which point vision loss can be sudden and, in some cases, irreversible. Screening therefore targets people who feel entirely healthy.

Pathophysiology Basics

Chronic high blood sugar damages small blood vessels throughout the body, and the retina — with its dense, delicate capillary network — is especially vulnerable. The sequence of events:

Capillary damage and weakening. Sustained hyperglycaemia injures the endothelial cells lining retinal capillaries and causes loss of pericytes (supporting cells). Vessel walls weaken.
Microaneurysms. The weakened capillary walls bulge outward, forming tiny outpouchings — microaneurysms. These are typically the earliest clinically visible sign of diabetic retinopathy.
Leakage. Damaged vessels leak fluid, lipids, and blood into the retinal tissue, producing haemorrhages (dot, blot, or flame-shaped) and hard exudates (yellow lipid deposits).
Capillary closure (ischaemia). Some capillaries shut down entirely, starving areas of retina of oxygen.
Neovascularisation. In response to ischaemia, the retina releases growth factors that stimulate the growth of new, abnormal blood vessels. These new vessels are fragile, grow on the retinal surface and into the vitreous, bleed easily, and can pull the retina off (tractional detachment). This is the proliferative stage — the dangerous turning point.

Diabetic macular edema (DME) — swelling of the macula from leaking vessels — can occur at any stage of retinopathy and is a major cause of vision loss in its own right.

Stages of Diabetic Retinopathy

Retinopathy is classified as non-proliferative (NPDR) or proliferative (PDR), based on whether abnormal new vessels are present.

Non-proliferative diabetic retinopathy (NPDR)

NPDR is graded by the number and severity of lesions — more lesions mean more advanced disease and higher risk of progression:

Mild NPDR. A few microaneurysms only. At this stage the disease is present but minimal; the main task is monitoring.
Moderate NPDR. Microaneurysms plus additional findings such as dot-and-blot haemorrhages and/or hard exudates. More extensive disease, but still no neovascularisation.
Severe NPDR. Extensive haemorrhages and microaneurysms in multiple quadrants of the retina, venous beading (irregular calibre of veins), or intraretinal microvascular abnormalities (IRMA — abnormal shunting vessels within the retina). Severe NPDR carries a high risk of progressing to proliferative disease and warrants close surveillance.

Proliferative diabetic retinopathy (PDR)

Defined by the presence of neovascularisation — new abnormal vessels on the optic disc (NVD) or elsewhere on the retina (NVE).
These vessels are fragile and prone to bleeding into the vitreous (vitreous haemorrhage — sudden vision loss), and their associated fibrous tissue can contract and detach the retina (tractional retinal detachment).
PDR can be further described as early or high-risk depending on the extent of new vessels and the presence of bleeding, but the key clinical point is: PDR needs prompt specialist treatment.

Diabetic macular edema (DME)

Thickening or swelling of the macula (the central retina responsible for detailed vision) due to leaking capillaries.
May be focal (leakage from identifiable microaneurysms) or diffuse (widespread capillary leakage).
Can occur at any NPDR stage and in PDR; it is the commonest cause of visual impairment in diabetic patients.
Clinically significant macular edema — particularly edema involving or threatening the centre of the macula — is a referral and treatment indication.

Stage Summary Table

Stage	Key findings	Significance
Mild NPDR	Microaneurysms only	Earliest detectable disease; routine monitoring
Moderate NPDR	Microaneurysms + haemorrhages/exudates	More extensive; closer follow-up
Severe NPDR	Extensive haemorrhages, venous beading, IRMA	High risk of progression to PDR; close surveillance
PDR	Neovascularisation (disc or elsewhere)	Prompt specialist treatment needed
DME (any stage)	Macular thickening/swelling	Referral and treatment indication

Screening Guidelines — General Principles

Because early disease is silent, screening is scheduled by time and risk, not by symptoms. Exact national protocols vary, but the general principles are consistent worldwide:

Who should be screened

All patients with diabetes — type 1 and type 2. Retinopathy risk exists in both.
Screening is a lifelong commitment for as long as the patient has diabetes.

When to start

Type 1 diabetes: screening typically begins a few years after diagnosis (retinopathy is rare in the first years), then continues regularly.
Type 2 diabetes: screening begins at the time of diagnosis, because type 2 diabetes is often present undiagnosed for years — retinopathy may already be there.
Pregnancy: diabetic women who are pregnant or planning pregnancy need eye examination, as pregnancy can accelerate retinopathy.
After the first screen, patients with no retinopathy are typically re-screened annually (some programs extend the interval after consistently clear screens — follow local protocol).
Patients with more advanced disease are reviewed more frequently — intervals shorten as severity increases.
Any sudden vision change in a diabetic patient warrants urgent assessment, not waiting for the next scheduled screen.

How screening is done

Dilated fundus examination by a trained examiner (optometrist or ophthalmologist) using slit-lamp biomicroscopy or indirect ophthalmoscopy.
Retinal photography (fundus cameras) is widely used in screening programs — images are captured, often without dilation, and graded by trained readers; abnormal results are referred for full examination.
OCT (optical coherence tomography) is the standard for detecting and quantifying macular edema.

The Role of the Optometrist in Screening

Optometrists sit at the centre of diabetic eye care in most health systems:

Primary screeners. In many countries, optometrists perform the bulk of routine diabetic eye examinations — dilated fundus exams, retinal photography, and OCT.
Graders. Trained optometrists grade screening images and assign the retinopathy stage, determining the recall interval or referral.
Referral decision-makers. Knowing exactly when a finding crosses the threshold for specialist referral (severe NPDR, any PDR, macular edema, unexplained vision loss) is a core competency.
Patient educators. The optometrist often explains to symptom-free patients why annual eye exams matter — and reinforces that good blood-sugar, blood-pressure, and cholesterol control protects their sight.
Coordinators. Optometrists link the eye findings back to the patient’s diabetes care team, closing the loop between eye health and systemic control.

Referral Criteria

Refer promptly to ophthalmology when any of the following is found:

Any proliferative disease (neovascularisation) — urgent.
Severe NPDR — close surveillance threshold; refer per local protocol.
Diabetic macular edema, especially involving or threatening the foveal centre.
Unexplained vision loss in a diabetic patient (consider vitreous haemorrhage or tractional detachment).
Sudden vision loss — emergency (possible vitreous haemorrhage or retinal detachment).
Any finding you cannot confidently grade — when in doubt, refer.

Treatment options the specialist may use (conceptual overview, not prescribing guidance): panretinal laser for PDR, intravitreal injections targeting vascular growth factors for DME and some PDR, and vitrectomy surgery for non-clearing vitreous haemorrhage or tractional detachment.

Prevention Through Glycaemic Control

The single most powerful intervention against diabetic retinopathy happens outside the eye clinic:

Good glycaemic control dramatically slows the onset and progression of retinopathy. This is the best-established fact in the field.
Blood pressure control independently reduces retinopathy risk and progression.
Lipid management contributes to overall vascular health.
Smoking cessation — smoking worsens microvascular disease.
Early and sustained control matters most: the benefit of good control in the early years of diabetes persists for decades (the “legacy effect”). Conversely, rapid tightening of very poor control should be done under medical supervision, as sudden improvement can transiently worsen retinopathy.

The optometrist’s message to every diabetic patient: your blood sugar control is eye treatment.

Key Takeaways

Diabetic retinopathy is retinal blood-vessel damage from chronic hyperglycaemia — a leading preventable cause of blindness in working-age adults.
Pathophysiology runs from capillary weakening → microaneurysms → leakage → ischaemia → neovascularisation (the proliferative turning point).
Stages: mild → moderate → severe NPDR (graded by lesion burden), then PDR (new abnormal vessels). DME (macular swelling) can occur at any stage.
Early disease is asymptomatic — screening is scheduled by time and risk, never by symptoms.
Type 2 diabetics are screened from diagnosis; type 1 typically a few years after diagnosis; pregnancy accelerates disease.
Optometrists are the primary screeners, graders, referral decision-makers, and patient educators in diabetic eye care.
Refer promptly for: any PDR, severe NPDR, macular edema, unexplained or sudden vision loss.
Glycaemic, blood pressure, and lipid control are the foundation of prevention — early sustained control has lifelong benefit.

This material is for educational purposes only and does not constitute medical advice. Clinical decisions should always involve qualified supervision.